GRTS - Is This Under-the-Radar COVID Stock the Next Moderna?
Gritstone Oncology (NASDAQ: GRTS) started the week as a little-known player in the coronavirus vaccine space. Its shares were trading at less than $10 apiece, and the market value totaled well under $1 billion. And then, in a blink of an eye, all of that changed. Its shares -- and market capitalization -- soared.
Why so much excitement? This clinical-stage company announced something that could address the biggest problem vaccine makers face right now: new strains of the coronavirus. Gritstone said its vaccine candidate targets that very problem. And the company aims to start a phase 1 trial this quarter. So, is Gritstone following Moderna 's (NASDAQ: MRNA) footsteps to stock market stardom? Let's take a look.
Image source: Getty Images.
For further details see:
Is This Under-the-Radar COVID Stock the Next Moderna?